文献速递乳腺癌支持与姑息治疗

地舒单抗预防接受雌二醇抑制治疗的绝经前乳腺癌女性的骨丢失和微结构恶化:一项随机对照试验

Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2024-07-02

这项12个月双盲随机试验纳入68例开始卵巢功能抑制联合芳香化酶抑制剂治疗的ER阳性早期乳腺癌绝经前女性,随机接受地舒单抗60 mg(n=34)或安慰剂(n=34)每6个月一次。地舒单抗阻止了胫骨远端总容积骨密度下降(组间校正均差20.8 mg HA/cm3,95%CI 17.3至24.2),并阻止腰椎、全髋和股骨颈骨密度下降,所有P<.001(除非另注)。

要点

  • 地舒单抗每6个月60 mg阻止了胫骨远端总骨密度下降,组间校正均差20.8 mg HA/cm3(95%CI 17.3至24.2)。
  • 地舒单抗阻止了腰椎骨密度下降,组间校正均差0.13 g/cm2(95%CI 0.11至0.15)。
  • 地舒单抗阻止了全髋和股骨颈骨密度下降,组间校正均差分别为0.08 g/cm2和0.06 g/cm2。

核心结论

  • 在开始雌二醇抑制治疗时使用地舒单抗可保留骨密度、骨微结构和估计骨强度,并可能提高无骨折生存。

研究设计与样本

  • 12个月双盲随机对照试验,纳入68例开始卵巢功能抑制和芳香化酶抑制剂治疗的ER阳性早期乳腺癌绝经前女性。
  • 随机分配至地舒单抗60 mg组(n=34)或安慰剂组(n=34),每6个月一次(第0和6个月)。
  • 主要终点为12个月内胫骨远端总容积骨密度的组间校正均差(MAD;[95%CI]),对所有时间点检验单一P值。
  • 试验注册于澳大利亚新西兰临床试验注册中心(ANZCTR;注册号:ACTRN12616001051437)。

主要发现

  • 12个月内,与安慰剂相比,地舒单抗阻止了胫骨远端总骨密度下降(MAD,20.8 mg HA/cm3 [95%CI,17.3至24.2])。
  • 地舒单抗阻止了胫骨远端皮质骨密度下降(MAD,42.9 mg HA/cm3 [95%CI,32.1至53.9])和小梁骨密度下降(MAD,3.32 mg HA/cm3 [95%CI,1.45至5.20],P = .004)。
  • 地舒单抗阻止了胫骨远端估计刚度下降(MAD,11.6 kN/m [95%CI,7.6至15.6])和失效载荷下降(MAD,563 N [95%CI,388至736])。
  • 桡骨远端结果相似;地舒单抗还阻止了腰椎骨密度下降(MAD,0.13 g/cm2 [95%CI,0.11至0.15])、全髋骨密度下降(MAD,0.08 g/cm2 [95%CI,0.07至0.09])和股骨颈骨密度下降(MAD,0.06 g/cm2 [95%CI,0.05至0.07])。
  • 除另有注明外,所有P < .001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Suppression of ovarian function and aromatase inhibition (AI) increases disease-free survival in premenopausal women with estrogen receptor (ER)-positive early-stage breast cancer but accelerates bone loss. We therefore hypothesized that suppressing bone remodeling using denosumab (DMAB) would prevent bone loss in these women. METHODS: In a 12-month double-blind randomized trial, 68 women with ER-positive early-stage breast cancer commencing ovarian function suppression and AI were randomly assigned to 60 mg DMAB (n = 34) or placebo (PBO; n = 34) once every 6 months (at 0 and 6 months). Volumetric bone mineral density (BMD), microarchitecture, and estimated bone strength of the distal tibia and distal radius were measured using high-resolution peripheral quantitative computed tomography, and spine and hip BMD were measured using dual-energy X-ray absorptiometry at 0, 6, and 12 months. The primary end point and treatment effect was the mean adjusted between group difference (MAD; [95% CI]) in distal tibial total volumetric BMD over 12 months, with a single P value tested over all time points. The study is registered with the Australian New Zealand Clinical Trials Registry (anzctr.org.au; identifier: ACTRN12616001051437). RESULTS: Intention-to-treat analysis included all 68 randomly assigned women. Over 12 months, compared with PBO, DMAB prevented the decrease in distal tibial total BMD (MAD, 20.8 mg HA/cm3 [95% CI, 17.3 to 24.2]), cortical BMD (42.9 mg HA/cm3 [95% CI, 32.1 to 53.9]), trabecular BMD (3.32 mg HA/cm3 [95% CI, 1.45 to 5.20], P = .004), estimated stiffness (11.6 kN/m [95% CI, 7.6 to 15.6]), and failure load (563 N [95% CI, 388 to 736]). Findings were similar at the distal radius. Decreases in BMD at the lumbar spine (MAD, 0.13 g/cm2 [95% CI, 0.11 to 0.15]), total hip (0.08 g/cm2 [95% CI, 0.07 to 0.09], and femoral neck (0.06 g/cm2 [95% CI, 0.05 to 0.07]) were also prevented. All P < .001 unless otherwise noted. CONCLUSION: Treatment with DMAB at commencement of estradiol suppression therapy preserves BMD, bone microarchitecture, and estimated strength, and is likely to increase fracture-free survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramchand SK, Ghasem-Zadeh A, Hoermann R, et al. Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial. J Clin Oncol. 2024. PMID: 38954783. doi:10.1200/JCO.23.02309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。